CMPX - Compass Therapeutics Inc Stock Price, Fair Value and News

$2.38+0.19 (+8.68%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

CMPX Price Action

Last 7 days

-2.1%

Last 30 days

12.8%

Last 90 days

6.3%

Trailing 12 Months

112.5%

CMPX RSI Chart

CMPX Valuation

Market Cap

329.1M

Price/Earnings (Trailing)

-5.96

Price/Sales (Trailing)

387.19

EV/EBITDA

-5.4

Price/Free Cashflow

-7.44

CMPX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

CMPX Fundamentals

CMPX Revenue

Revenue (TTM)

850.0K

CMPX Earnings

Earnings (TTM)

-55.2M

Earnings Growth (Yr)

-54.19%

Earnings Growth (Qtr)

-10.65%

CMPX Profitability

EBT Margin

-6342.47%

Return on Equity

-50.07%

Return on Assets

-42.01%

Free Cashflow Yield

-13.44%

CMPX Investor Care

Shares Dilution (1Y)

0.50%

CMPX Alerts

1 major insider buys recently.

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	850.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Compass Therapeutics Inc

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.

CEO	Dr. Thomas J. Schuetz M.D., Ph.D.
WEBSITE	compasstherapeutics.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	26

Compass Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Compass Therapeutics Inc? What does CMPX stand for in stocks?

CMPX is the stock ticker symbol of Compass Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Compass Therapeutics Inc (CMPX)?

As of Wed Jun 18 2025, market cap of Compass Therapeutics Inc is 329.11 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CMPX stock?

You can check CMPX's fair value in chart for subscribers.

Is Compass Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether CMPX is over valued or under valued. Whether Compass Therapeutics Inc is cheap or expensive depends on the assumptions which impact Compass Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CMPX.

What is Compass Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Jun 18 2025, CMPX's PE ratio (Price to Earnings) is -5.96 and Price to Sales (PS) ratio is 387.19. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CMPX PE ratio will change depending on the future growth rate expectations of investors.